Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

By G. Döring, S. Conway, H. Heijerman, M. Hodson, Niels Høiby, A. Smyth, D. Touw. European Respiratory Journal, 2000

635 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/084c993c4ec4774059d0bb43e417e20295a2c93a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. T. Bjarnsholt
2. Marin Kollef
3. D. Livermore

Citations in the corpus

• Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections (2016, background): “Given that CF patients are subjected to prolonged and often intensive therapy with antibiotics [18], the evolution of antibiotic resistances is also a common adaptation [19].”
• The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections (2012, methodology): “aeruginosa when alternative agents are nosa, mention should be made of a recent prospecavailable; and (ii) consensus statements on the treat- tive study of treatment duration for VAP, which ment of CF recommend combination anti- found no difference in clinical outcomes among pseudomonal therapy for ”
• ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. (2015, background): “conductive compartments of the lungs [30,31,33,34,184] (AI).”
• Pathophysiology and management of pulmonary infections in cystic fibrosis. (2003, background): “aeruginosa infection (250) on the basis of findings from several studies of eradication and delayed reinfection with this pathogen (248, 251, 252).”
• Genome-wide identification of novel small RNAs in Pseudomonas aeruginosa (2013, background): “After the introduction of strand-specific RNA-seq protocols the number of asRNAs detected has increased exponentially, with tens to hundreds of asRNAs detected in every bacterium studied (15,24-30).”
• Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. (2007, background): “Arguments in favour include the easier eradication of non-mucoid morphotypes, which can protect patients from further colonisation for several years [132,134,138].”
• Antibiotic resistance of bacterial biofilms. (2010, neutral): “therapy when clinical deterioration ccurs [108].”
• Bacterial resistance: origins, epidemiology, and impact. (2003, background): “, erythromycin) often ameliorate the symptoms of infection [76].”
• Lung Infections Associated with Cystic Fibrosis (2002, background): “While monotherapy may be as effective against susceptible strains, combination therapy is clearly more effective against resistant strains and may delay the development of resistance (80).”
• Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence (2017, background): “P. aeruginosa will adapt to CF airways and persist as overwhelming, predominant and ineradicable infections to the end of patients’ life in almost 70% of adults (Döring et al., 2000).”